Table 1.
Patients clinical and pathological characteristics.
| Characteristics | Patients (n [%]) | |
| Gender |
Female | 51 (39.8) |
| Male | 77 (60.2) | |
| Age (years) | <60 | 58 (45.3) |
| ≥60 | 70 (54.7) | |
| ECOG PS | ≤1 | 69 (53.9) |
| 2 | 59 (46.1) | |
| Smoking history | No | 63 (49.2) |
| Yes | 65 (50.8) | |
| EGFR status | Wild-type | 25 (19.5) |
| Mutation | 10 (7.8) | |
| Unknown | 93 (72.7) | |
| Number of metastases | 0 | 33 (25.8) |
| ≤2 | 54 (42.2) | |
| ≥3 | 41 (32.0) | |
| Pre-radiotherapy | No | 54 (42.2) |
| Yes | 74 (57.9) | |
| Pathology | AD | 90 (70.3) |
| SCC | 16 (12.5) | |
| Others | 22 (17.2) | |
| Apatinib dose (mg/d) | -500 | 104 (81.3) |
| >500 | 24 (18.7) | |
| Line of Apatinib | Second line | 10 (7.8) |
| Further line | 118 (92.2) | |
| TNM stage | III | 61 (47.7) |
| IV | 67 (52.3) | |
| Hypertension during treatment | No | 80 (62.5) |
| Yes | 48 (38.4) | |
| Proteinuria during treatment | No | 93 (72.7) |
| Yes | 35 (27.3) | |
| HFS during treatment | No | 98 (76.6) |
| Yes | 30 (23.4) |
1 ECOG PS, Eastern Cooperative Oncology Group performance status; 2 AD, adenocarcinoma;3 SCC, squamous cell carcinoma; 4 TNM, tumor, node, and metastases; 5 HFS, hand-foot syndrome.